Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR1B | P28222 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481804 | 0.80 | HTR6 (0.56) | HTR6HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL4475099 | 0.80 | HTR6 (0.58) | HTR6HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3957243 | 0.79 | HTR6 (0.48) | HTR6HTR2AHTR2C | |
| SCHEMBL4495166 | 0.78 | HTR6 (0.56) | HTR6HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3952442 | 0.77 | HTR6 (0.61) | HTR6HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3951001 | 0.72 | HTR6 (0.64) | HTR6HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL6588526 | 0.71 | HTR6 (0.77) | HTR6 | |
| SCHEMBL30394234 | 0.68 | HTR6 (0.58) | HTR6HTR2CHTR2BHTR1ASLC6A2 | |
| SCHEMBL28311472 | 0.68 | HTR6 (0.58) | HTR6HTR2CHTR2BHTR1ASLC6A2 | |
| SCHEMBL4658523 | 0.68 | HTR6 (0.60) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | claimed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | claimed |
| JP-2006517966-A | — | — | 2006-08-03 | — | — | JP | claimed |
| EP-1592690-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004074286-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR2A 8/4885HTR2C 3/4885 |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885HTR2A 7/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.